Patents Assigned to MuPharma Pty Ltd
  • Patent number: 12521540
    Abstract: There is disclosed systems and methods for non-invasive delivery of an agent to biological tissues. Delivery of the agent to the tissues can be by one or more modalities. In some embodiments the systems and methods use agent carrier body including a tissue contacting surface for non-invasively engaging tissues under treatment. The tissue contacting surface can be at least partly defined by a plurality of protrusions that are in fluid communication with one or more reservoirs forming part of the agent carrier body. The protrusions may extend outward from an inside of a void and terminate at said tissue contacting surface.
    Type: Grant
    Filed: May 30, 2024
    Date of Patent: January 13, 2026
    Assignee: MuPharma Pty Ltd
    Inventors: Harry Unger, Mark Unger, Sean Michael Langelier
  • Patent number: 12115333
    Abstract: There is disclosed systems and methods for non-invasive delivery of an agent to biological tissues. Delivery of the agent to the tissues can be by one or more modalities. In some embodiments the systems and methods use agent carrier body including a tissue contacting surface for non-invasively engaging tissues under treatment. The tissue contacting surface can be at least partly defined by a plurality of protrusions that are in fluid communication with one or more reservoirs forming part of the agent carrier body. The protrusions may extend outward from an inside of a void and terminate at said tissue contacting surface.
    Type: Grant
    Filed: April 29, 2021
    Date of Patent: October 15, 2024
    Assignee: MuPharma Pty Ltd
    Inventors: Harry Unger, Mark Unger, Sean Michael Langelier
  • Patent number: 12029873
    Abstract: There is disclosed systems and methods for non-invasive delivery of an agent to biological tissues. Delivery of the agent to the tissues can be by one or more modalities. In some embodiments the systems and methods use agent carrier body including a tissue contacting surface for non-invasively engaging tissues under treatment. The tissue contacting surface can be at least partly defined by a plurality of protrusions that are in fluid communication with one or more reservoirs forming part of the agent carrier body. The protrusions may extend outward from an inside of a void and terminate at said tissue contacting surface.
    Type: Grant
    Filed: July 27, 2020
    Date of Patent: July 9, 2024
    Assignee: MuPharma Pty Ltd
    Inventors: Harry Unger, Sean Michael Langelier, Mark Unger
  • Publication number: 20160101273
    Abstract: An agent carrier delivers an agent to biological tissues by one or more modalities. The modality of delivery may be one or more transportation stimulus that causes the agent to be transported through the agent carrier. The transportation stimulus also enhances or permits penetration of the agent into the tissue. The agent carrier has an agent carrier body that is configured to retain the agent within the agent carrier body. The agent carrier body has a tissue-contacting surface for engaging tissues under treatment. Application of the transportation stimulus causes transportation of the agent through the agent carrier body to the tissue-contacting surface.
    Type: Application
    Filed: May 6, 2014
    Publication date: April 14, 2016
    Applicant: MuPharma Pty Ltd
    Inventors: Harry Unger, Sean Michael Langelier, Mark Unger